Trump Administration Accelerates Review of Psychedelic Therapies for Veterans President Donald Trump signed an executive order to expedite the FDA review of psychedelic drugs for treating PTSD and traumatic brain injuries in military veterans, citing promising research and the urgent need for new mental health solutions. President Donald Trump has signed an executive order aimed at significantly speeding up the review process for psychedelic drugs that show promise in treating conditions like post-traumatic stress disorder (PTSD) and traumatic brain injuries, particularly for military veterans. During a press conference in the Oval Office, Trump emphasized the critical need for new treatments for veterans, highlighting the ongoing suicide epidemic within this population as a national tragedy. He cited concerning statistics, noting that since 9/11, significantly more veterans have died by suicide than in combat. The President expressed hope that these new avenues of research and treatment would lead to a substantial reduction in veteran suicides. To underscore the potential of these therapies, President Trump referenced a 2024 study from Stanford University. This study involved 30 special operations veterans who had experienced traumatic brain injuries. After undergoing treatment with ibogaine, a psychedelic substance, these veterans reportedly saw an 80% to 90% decrease in symptoms of depression and anxiety within a single month. Despite ibogaine and other psychedelics currently being classified as highly restricted illegal drugs under federal law, the Trump administration is actively working to reduce these restrictions and encourage medical research. The executive order specifically directs the Food and Drug Administration (FDA) to prioritize and expedite applications for treatments that have demonstrated early success in clinical trials for PTSD, traumatic brain injury, depression, anxiety, and other mental health challenges. The FDA's existing breakthrough therapy designation, intended for drugs showing significant improvement over current options, is expected to be utilized more rapidly under this new directive, aiming to shorten the time it takes for these promising therapies to become accessible to patients. The signing ceremony in the Oval Office was attended by key health officials, notable podcaster Joe Rogan, and Marcus Luttrell, a former Navy SEAL whose experiences were depicted in the film Lone Survivor. Luttrell expressed his belief that the order would save lives, personally attesting to the positive impact these treatments can have. Joe Rogan shared an anecdote about the swift nature of the President's decision-making upon receiving information about these therapies, suggesting a rapid approval process. Rogan also commented on the historical context of psychedelic prohibition, arguing that the 1970 Controlled Substances Act under the Nixon administration was motivated by a desire to target social movements rather than by inherent harm from the substances themselves. However, not all reactions were positive. Critics have voiced concerns that accelerating the FDA’s approval process could compromise safety and oversight, emphasizing the paramount importance of thorough and rigorous clinical trials before any widespread adoption. The administration's move has also surprised many in the psychedelic research community, especially given ibogaine's known potential for serious cardiovascular side effects. The National Institutes of Health had previously funded research on ibogaine in the 1990s but halted the work due to concerns about its cardiotoxicity. Experts like Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, acknowledge the challenges in studying ibogaine due to its cardiotoxicity but express hope that the executive order might facilitate objective scientific research to better understand its therapeutic potential compared to other psychedelics. Currently, no psychedelic has received FDA approval in the U.S., though substances like psilocybin, MDMA, and LSD are undergoing large-scale clinical trials for various mental health conditions